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Abstract
Background: The etiology of many chronic diseases involves interactions between environmental
factors and genes that modulate physiological processes. Understanding interactions between
environmental chemicals and genes/proteins may provide insights into the mechanisms of chemical
actions, disease susceptibility, toxicity, and therapeutic drug interactions. The Comparative
Toxicogenomics Database (CTD; http://ctd.mdibl.org) provides these insights by curating and
integrating data describing relationships between chemicals, genes/proteins, and human diseases.
To illustrate the scope and application of CTD, we present an analysis of curated data for the
chemical arsenic. Arsenic represents a major global environmental health threat and is associated
with many diseases. The mechanisms by which arsenic modulates these diseases are not well
understood.
Methods: Curated interactions between arsenic compounds and genes were downloaded using
export and batch query tools at CTD. The list of genes was analyzed for molecular interactions,
Gene Ontology (GO) terms, KEGG pathway annotations, and inferred disease relationships.
Results: CTD contains curated data from the published literature describing 2,738 molecular
interactions between 21 different arsenic compounds and 1,456 genes and proteins. Analysis of
these genes and proteins provide insight into the biological functions and molecular networks that
are affected by exposure to arsenic, including stress response, apoptosis, cell cycle, and specific
protein signaling pathways. Integrating arsenic-gene data with gene-disease data yields a list of
diseases that may be associated with arsenic exposure and genes that may explain this association.
Conclusion:  CTD data integration and curation strategies yield insight into the actions of
environmental chemicals and provide a basis for developing hypotheses about the molecular
mechanisms underlying the etiology of environmental diseases. While many reports describe the
molecular response to arsenic, CTD integrates these data with additional curated data sets that
facilitate construction of chemical-gene-disease networks and provide the groundwork for
investigating the molecular basis of arsenic-associated diseases or toxicity. The analysis reported
here is extensible to any environmental chemical or therapeutic drug.
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Background
Environmental chemicals are postulated to play a critical
role in the etiology of many human diseases [1-4]. To
understand the impact of environmental chemicals on
human health, we have developed the Comparative Toxi-
cogenomics Database (CTD) [5,6]. CTD curates and inte-
grates toxicogenomic data from vertebrates and
invertebrates, including 124,000 chemicals, 2.6 million
gene and protein sequences and their associated Gene
Ontology (GO) [7] and KEGG pathway annotations [8],
128,000 taxa and 6,300 human diseases to produce a
unique resource for the cross-species analysis of chemi-
cals, genes and proteins, diseases, and their complex inter-
actions. Biocurators at CTD curate three types of data from
the scientific literature: (1) chemical-gene/protein interac-
tions, (2) chemical-disease relationships, and (3) gene/
protein-disease relationships. These data are curated in a
structured format using controlled vocabularies and
ontologies for chemicals, genes/proteins, diseases, molec-
ular interactions, and organisms. Curated gene-disease
relationships in CTD are integrated with data from the
Online Mendelian Inheritance in Man (OMIM) database
[9]. Over 110,000 molecular interactions involving 3,700
chemicals and 13,200 genes from 260 species have been
curated to date. CTD also contains curated data for more
than 5,700 and 2,000 gene-disease and chemical-disease
relationships, respectively. CTD provides a unique per-
spective about chemical-gene-disease relationships by
integrating data curated from the scientific literature. All
interactions are linked to the original publications, allow-
ing users to access the source data for specific details about
corresponding experiments (e.g., dose-response, assay,
tissue).
To demonstrate the scope and utility of the database for
developing hypotheses about chemical-gene/protein-dis-
ease networks in humans, we analyzed the CTD arsenic
data set as a test case. Arsenic is a global environmental
toxicant, and its harmful effects can occur at very low
exposure levels. It is a naturally occurring element, but is
also a contaminant from industrial pollution, coal com-
bustion, mining, metal processing, and the use of pesti-
cides and fertilizers [10]. The potential health costs of
chronic arsenic exposure are staggering, with over 500
million people at risk of exposure to contaminated water
in eastern India and Bangladesh alone [11]. In certain
regions of the United States, contaminated well-water is a
significant health concern due to arsenic concentrations
far exceeding the guidelines established by the Environ-
mental Protection Agency [12]. Despite the diverse and
serious health implications of arsenic exposure, its molec-
ular mechanisms of action remain largely unknown,
thereby hampering efforts to more accurately predict and
treat associated toxicities.
Here we analyze our curated arsenic-gene interaction data
and illustrate how CTD can be used to predict both
arsenic-associated diseases and the impact of arsenic
exposure on molecular functions and gene networks.
Henceforth, "arsenic" is used to describe all arsenic con-
taining compounds and the term, "gene" includes all
forms of the gene (e.g., mRNA, protein) unless otherwise
stated.
Methods
Curation process
Chemical-gene interaction
Candidate references for curation in CTD are collected by
querying PubMed [13] for the co-occurrence of relevant
gene and chemical terms. Controlled vocabulary terms
from the National Library of Medicine's Medical Subject
Headings (MeSH) [14] are used to search titles and
abstracts. For the arsenic literature corpus, we initially
queried PubMed with the terms "gene" and "arsenic" or
"arsenical" as strings and MeSH-tagged terms. Since MeSH
is a hierarchical vocabulary, use of MeSH as a query term
descriptor allows retrieval of references with "child"
chemical terms for arsenicals (e.g., sodium arsenite).
Arsenic and arsenicals were both used because they reside
in distinct hierarchical paths in the MeSH vocabulary.
Among the 572 papers identified, 330 published between
2001 and 2007 were reviewed for curation; since then,
additional papers describing arsenic-gene interactions
have also been added to the database. Although this cor-
pus did not include all references describing arsenic-gene
interactions, it represented the most recent references ana-
lyzing molecular mechanisms of arsenic compounds. Sci-
entific curators read abstracts or full-text articles and
recorded all interactions between arsenic and a gene or
protein. Curated data included: PubMed identification
number, molecular interaction (using CTD curation
action codes described below), interacting chemical,
interacting gene, and the species in which the interaction
occurred. Curators used the most specific chemical term
possible from the CTD chemical vocabulary (see CTD
controlled vocabularies below). In cases where only
generic terms like "arsenic" were used in the abstract, the
full text was consulted to determine the specific com-
pound used (e.g., sodium arsenite). Biocurators do not
manipulate, standardize, or normalize data from publica-
tions. Interactions reflect the authors' own conclusions. In
cases in which authors describe microarray experiments,
biocurators adhere to the authors' stated levels of signifi-
cance when curating the data. Consequently, it is possible
to find contradictory data in CTD, which reflect differ-
ences in experimental details and conclusions from differ-
ent manuscripts. Users can explore these discrepancies by
accessing the original papers associated with each interac-
tion. Biocurators collect data from both the main text andBMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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supplementary files for a paper when appropriate or pos-
sible.
Curated interaction analysis
All curated interaction data in CTD are publicly available.
The arsenic analysis reported here is based on data down-
loaded and analyzed in March 2008. Prior to analysis, the
data set was first manually processed as follows:
1. Curated interactions for arsenic compounds were com-
bined. Interactions for both arsenic and arsenicals were
retrieved using the CTD Curated Interaction Query [15].
The query was a "contains" search using the term "arsenic"
in the Chemical query box and "ANY" as the chemical-
gene interaction type. This query retrieved all curated
interactions for arsenic, arsenicals, and all child terms.
2. "No effect" interactions were removed. In addition to
capturing chemical-gene interactions, curators capture
"no effect" results reported in the literature, such as
"arsenic trioxide does not affect the phosphorylation of
protein A." To avoid artificially inflating the number of
interactions involving arsenic or falsely associating arsenic
with a gene, all "no effect" interactions were removed
from the data set.
3. Binary interactions were identified. A curated interac-
tion in CTD must include at least one chemical and one
gene (binary interaction); however, complex interactions
describing more than two molecules may also be cap-
tured. For example, the following two interactions were
curated from the same paper: "arsenite results in increased
expression of TP53 mRNA" and "alpha-tocopherol inhib-
its the reaction [arsenite results in increased expression of
TP53 mRNA]." The first interaction is binary and describes
the core data (arsenite exposure leads to up-regulated
TP53 mRNA). The second interaction is complex in that it
reiterates the core data and then qualifies it with addi-
tional information. To avoid inclusion of duplicate inter-
actions from a single reference, only binary interactions
were retained in the data set.
CTD controlled vocabularies
Several controlled vocabularies and ontologies are used to
construct chemical-gene interactions and chemical- and
gene-disease relationships, allowing data to be captured
consistently by different curators, retrieved more easily
and reproducibly by users, and integrated with other data-
bases. Biocurators use official terms (gene symbol, chem-
ical name, or disease name) from standardized sources
(below). CTD is updated monthly, using the most current
release of all external databases that are integrated with
CTD (see "Data Status" link on CTD homepage for spe-
cific release versions). If an official term undergoes a
nomenclature change, CTD implements that same
change. Consequently, CTD is synchronized regularly
with its external data sources.
1. Chemicals. The CTD chemical vocabulary derives from
a modified subset of the chemicals and supplementary
concepts in the "Drugs and Chemicals" category of MeSH.
2. Chemical qualifiers. A chemical term can be qualified
with "analog" or "metabolite" to describe a chemical
derivative (e.g., arsenic disulfide analog or arsenic metab-
olite).
3. Diseases. The CTD disease vocabulary uses terms from
both MeSH and OMIM. To utilize both sources, we first
integrated OMIM disease names (a flat list) into the MeSH
disease hierarchy. Most OMIM diseases easily mapped to
a single equivalent term from MeSH (e.g., OMIM "lung
cancer" maps directly to MeSH "lung neoplasm"). Some
OMIM disease names were mapped to multiple MeSH
terms when a single equivalent term was not available
(e.g., OMIM "chronic myeloproliferative disorder with
eosinophilia" was most accurately mapped to two MeSH
terms: "myeloproliferative disorders" and "eosi-
nophilia"). This mapping preserved individual diseases
but rooted them in a hierarchical vocabulary, allowing a
user to cluster what might at first appear to be unrelated
diseases (e.g., "Papillon-Lefevre syndrome" and "multiple
café-au-lait spots") via a more general parent disease (e.g.,
"skin diseases").
4. Genes. CTD uses official gene symbols and names from
the National Center for Biotechnology Information's
(NCBI) Entrez-Gene database [16].
5. Gene qualifiers. A gene symbol can be qualified with
any of 15 gene qualifier terms developed at CTD (e.g.,
"DNA," "promoter," "mRNA," "protein," etc.) to specify
any aspect of a gene. Henceforth, we use the word "gene"
in this paper to collectively refer to any aspect of a gene,
including its product.
6. Action codes. CTD curators developed a hierarchical
vocabulary of 50 diverse terms (e.g., "binding," "phospho-
rylation," "activity," "transport," "methylation") to
describe the specific molecular interaction between any
chemical and gene. A complete list of action codes and
their definitions is available via the Help link for interac-
tions on CTD glossary page and gene, interaction, and ref-
erence query forms.
7. Organisms. The CTD organism vocabulary consists of
the Eumetazoa portion (vertebrates and invertebrates) of
the NCBI Taxonomy database [17].BMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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Gene function and network analysis
GO and KEGG pathway data are integrated with CTD gene
data. Annotations were downloaded for arsenic-interact-
ing genes using the CTD batch query tool. Network anal-
yses were performed using the Ingenuity Pathways
Analysis (Ingenuity Systems) software.
Disease analysis
There are two sources for direct disease relationships in
CTD: curation of chemical-disease and gene-disease rela-
tionships from the literature, and integration of gene-dis-
ease relationships from the OMIM database [9]. Disease
relationships in CTD may be direct or inferred. Direct rela-
tionships are established by CTD curation and imported
from OMIM. Inferred relationships are generated compu-
tationally by integrating curated chemical-gene data with
curated gene-disease data. For example, if Chemical A
interacts with Gene B (via a curated chemical-gene inter-
action), and independently Gene B is associated with Dis-
ease C (via a curated gene-disease molecular mechanism
or biomarker relationship), then Chemical A is said to
have an inferred relationship with Disease C (inferred via
Gene B). Disease relationships are clearly labeled as either
direct or inferred in CTD. Of the 1,456 genes that interact
with arsenic, 424 genes have a direct mechanism or
biomarker relationship with 516 unique diseases. To
identify whether there was a pattern among these 516 dis-
eases, the diseases were rooted to their top-leveled MeSH
terms and clustered into 26 categories. For example, type
1 diabetes mellitus is associated with three paths of the
MeSH disease hierarchy that ultimately are rooted to three
top-level disease categories: metabolic diseases, endocrine
system diseases, and immune system diseases. Conse-
quently, any arsenic-interacting gene directly associated
with type 1 diabetes mellitus is counted in all three of
those disease categories. The final distribution pattern for
these disease categories was compared against the disease
category distribution pattern for all disease-associated
genes in CTD. A Pearson's chi-square test comparing
arsenic associated diseases (derived from 424 arsenic-
interacting genes) indicated that these associations were
highly significant (p-value < 0.0001).
Results
A curated data set for arsenic was analyzed to illustrate the
scope of CTD and to highlight potential applications for
understanding mechanisms of chemical actions and
potential links to human diseases. This analysis included
2,738 curated interactions between 21 arsenic com-
pounds and 1,456 genes and proteins in 17 species. These
data were extracted from 280 papers published between
2001–2007.
Arsenic compounds
Sodium arsenite, arsenic trioxide, and sodium arsenate are
the three most frequently curated arsenic compounds in
CTD, interacting with 793, 500, and 230 genes, respec-
tively (Table 1). Despite the complex chemistry and
biotransformation of arsenic compounds, many (e.g.,
sodium arsenite and arsenic trioxide) are metabolized
into a common reactive arsenite ion [18]. To determine
whether different arsenic compounds affect similar genes,
we compared the interacting gene sets for these top three
arsenic compounds. Collectively, sodium arsenite, arsenic
trioxide, and sodium arsenate had curated interactions
with 1,297 genes, accounting for 89% of the total genes
analyzed in this arsenic study. Among these genes, 206
overlapped with at least two compounds, with the least
overlap found between sodium arsenate and arsenic triox-
ide (Figure 1). Twenty genes interacted with all three
arsenic compounds. These data indicate that arsenic com-
pounds share some common molecular activity, although
the overall biological effects or the molecular networks
they invoke may be compound-specific. Analysis of all
1,456 genes associated with all 21 arsenic compounds
accounts for primary and secondary targets of arsenic and
its metabolites. This approach may reasonably mimic a
biological response to arsenic. It is the combination of pri-
mary, secondary and metabolite effects that contribute to
the overall response to an exposure.
Molecular actions of arsenic
Curated chemical-gene interactions in CTD indicated that
arsenic has a broad range of molecular effects (Table 2).
The most common arsenic interaction involved effects on
transcription: 810 genes were up-regulated and 652 were
down-regulated. Arsenic also affected protein activity,
Table 1: Arsenic compounds with curated gene interactions
Arsenic Compounds Genes1
Sodium arsenite 793
Arsenic trioxide 500
Sodium arsenate 230
Arsenic 127
Arsenite 115
Arsenic disulfide 54
Dimethylarsinous acid 28
Gallium arsenide 19
Cacodylic acid 17
Monomethylarsonic acid 17
Arsenates 16
Arsenic trichloride 8
Trimethylarsine oxide 8
Dimethylarsine 7
Methylarsine oxide 6
Arsenic trisulfide 5
Arsenic acid 4
Oxophenylarsine 3
Arsenicals 2
Arsenous acid 1
Lewisite 1
1Some genes interact with more than one arsenic compoundBMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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phosphorylation status, degradation, localization, secre-
tion, metabolism, and stability. Promoter methylation
and gene mutagenesis effects of arsenic were also
described. Molecular interactions involving effects of pro-
teins on arsenic included resistance/susceptibility to
arsenic, arsenic metabolism, arsenic transport, and arsenic
binding.
Arsenic-interacting genes
Gene Ontology (GO) annotations and KEGG pathway
data are integrated in CTD to provide additional biologi-
cal context to genes and chemical effects. GO annotates
gene products in terms of their associated molecular func-
tion, biological process, and cellular component [7].
KEGG is a public resource that presents information
about molecular reaction networks [8]. Arsenic-interact-
ing genes were evaluated using GO, KEGG, and Ingenuity
Pathway Analysis (IPA) to gain insight into the biological
functions and molecular networks that may be altered by
arsenic exposure.
The top 25 genes with curated arsenic interactions
included several transcription factors (JUN, MYC, TP53,
EGR1, ESR1, DDIT3, FOS) and regulators of cell cycle, cell
proliferation, and apoptosis (BCL2, CCND1, CDKN2A,
VEGFA, CDNK1A, GADD45A, BAX), suggesting that a
dramatic cellular response may be induced by arsenic
exposure (Table 3). Seven of these genes (HMOX1,
CCND1, CDKN2A, GADD45A, GSTP1, DDIT3, FOS)
interact with multiple arsenic compounds (Figure 1).
GO and KEGG pathway annotations for all arsenic-inter-
acting genes in CTD were evaluated and comprised 1,042
distinct molecular functions, 2,093 biological processes,
383 cellular components, and 182 pathways (Table 4).
The most prominent annotated terms from each category
included protein binding (GO: molecular function); tran-
scription or signal transduction (GO: biological proc-
esses); nucleus, cytoplasm, or membrane (GO: cellular
component); and MAPK signaling pathway (KEGG).
Other frequently annotated processes and pathways for
the 1,456 genes included apoptosis, cell cycle, cell prolif-
eration, immune response, and cell signaling (Table 4).
These processes and pathways were also implicated when
using only the top 25 genes with curated arsenic interac-
tions (Table 3), suggesting that this subset of genes may
accurately represent the overall biology of genes respond-
ing to arsenic exposure.
To provide a more detailed view of molecular networks
potentially affected by arsenic, IPA was used to analyze
arsenic-interacting genes in CTD. Analysis of the 1,376
genes with annotations in the IPA database identified a
large arsenic-modulated interaction network comprising
105 proteins (Figure 2; see additional file 1). Pathway
analysis showed that the network was enriched with roles
in cell cycle control, apoptosis, and DNA repair, and was
associated significantly with cancer. The network con-
tained transcriptional regulators (28 proteins), enzymes
(18 proteins), cytokines (4 proteins), ligand-dependent
nuclear receptors (4 proteins), transmembrane receptors
(3 proteins) and peptidases (2 proteins). Locations of the
proteins within the network were distributed among the
Venn diagram of arsenic-interacting genes Figure 1
Venn diagram of arsenic-interacting genes. Sodium 
arsenite, arsenic trioxide, and sodium arsenate interact with 
793, 500, and 230 genes, respectively. The 20 genes common 
to all three arsenic compounds are listed.
Table 2: Types of curated arsenic-gene interactions
Arsenic-to-Gene Molecular Interactions Genes1
mRNA up-regulated 810
mRNA down-regulated 652
Protein up-regulated 97
mRNA/protein altered2 82
Protein activity 78
Protein down-regulated 49
Protein phosphorylation 39
Protein cleavage/degradation 14
Protein localization 14
Protein secretion 8
Promoter methylation 7
Protein metabolism 6
mRNA/protein stabilization 4
Gene mutagenesis 4
Gene-to-Arsenic Molecular Interactions Genes1
Arsenic resistance/susceptibility 43
Arsenic transport 5
Arsenic metabolism 5
Protein binds arsenic 5
1 Some genes are counted in more than one interaction category
2 Molecule (mRNA or protein) and/or direction (up or down-
regulation) were not specifiedBMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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nucleus (52 proteins), cytoplasm (27 proteins), extracel-
lular space (8 proteins) and plasma membrane (8 pro-
teins). Biological implications of this network are
consistent with GO, KEGG, and disease associations iden-
tified by other methods and described in this report.
Arsenic-gene-disease associations
Curated direct chemical-gene interactions and direct gene-
disease associations in CTD are integrated to create
inferred chemical-disease relationships. For example, if
Chemical A interacts with Gene B (via a curated chemical-
gene interaction), and Gene B is associated independently
with Disease C (via a curated gene-disease relationship),
then CTD presents an inferred relationship between
Chemical A and Disease C (inferred via Gene B). We
assessed whether it was valid to use these inferred rela-
tionships to predict diseases influenced by environmental
chemicals.
Among the genes with curated arsenic interactions in
CTD, 424 have curated relationships with 516 diseases.
Therefore, arsenic has inferred relationships with 516 dis-
eases in CTD. Using the hierarchical disease vocabulary in
CTD, these diseases were clustered into 26 general catego-
ries (see Methods). The most common disease categories
associated with arsenic included neoplasms, nervous sys-
tem diseases, skin diseases, digestive system diseases, met-
abolic disorders, and immune system diseases (Table 5).
Notably, many of these diseases were corroborated in the
literature as being associated with arsenic, including
malignancies (skin, lung, liver, kidney and bladder can-
cer), neurological defects (peripheral neuropathy and cog-
nitive impairment), skin lesions, diabetes, and many
others (Figure 3) [19-21]. This corroboration supported
the value of using CTD-inferred disease relationships to
develop novel hypotheses about the health effects of
exposure to environmental chemicals.
CTD provides candidate genes that may help to explain
mechanisms underlying chemical-disease relationships.
Cancer was the disease category most frequently associ-
ated with arsenic via curated interactions with 177 genes
in CTD. These diseases were subdivided into specific types
of malignancies, each with a unique set of associated
Table 3: Most frequently curated arsenic-interacting genes
No. 
Curated 
Interactions
No. 
Interacting 
As 
Compounds1
Gene Molecular 
Function2
Biological 
Process2
44 9 HMOX1 Heme oxygenase Heme oxidation
21 3 BCL2 Protein binding Regulation of apoptosis
21 6 JUN Transcription factor Regulation of transcription, DNA-dependent
19 6 ABCC2 ATP-binding transporter Transport
19 6 MAPK1 MAP kinase Protein amino acid phosphorylation
18 6 MAPK3 MAP kinase Protein amino acid phosphorylation
17 5 ABCC1 ATP binding Transport
17 4 CCND1 CDK regulator Regulation of cell cycle
17 5 CDKN2A Kinase Cell cycle arrest; regulation of cyclin dependent 
protein kinase activity
16 6 AS3MT S-adenosylmethionine-dependent 
methyltransferase
Arsonoacetate metabolism; toxin metabolism
16 3 MYC Transcription factor Regulation of transcription, DNA-dependent
15 3 VEGFA Growth factor Angiogenesis; anti-apoptosis; cell cycle
14 4 GADD45A Protein binding Cell cycle arrest; DNA damage response
14 6 NQO1 NADPH dehydrogenase Electron transport
14 4 TP53 Transcription factor Regulation of transcription, DNA-dependent
13 5 AFP Carrier Transport
13 4 CDKN1A CDK inhibitor Cell cycle arrest
13 4 GSTP1 Glutathione transferase Metabolism
13 3 HSPA1A Unfolded protein binding Protein folding; response to unfolded protein
12 5 EGR1 Transcription factor Regulation of transcription, DNA-dependent
12 4 ESR1 Transcription factor Regulation of transcription, DNA-dependent
12 4 PCNA DNA polymerase processivity factor; DNA 
binding
Regulation of DNA replication
11 5 DDIT3 Transcription factor Regulation of transcription, DNA-dependent
11 3 FOS Transcription factor Regulation of transcription, DNA-dependent
10 2 BAX Protein binding Regulation of apoptosis
1 Out of 21 total arsenic compounds curated from the literature (see Table 1)
2 Most frequently annotated GO terms are shown; complete list is available at CTDBMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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genes: breast (49 genes), stomach (42 genes), leukemia
(23 genes), nervous system (19 genes), lung (18 genes),
colon (17 genes), bladder (15 genes), and others (Table
6). Although some of these disease associations have been
documented (e.g., lung cancer), the molecular mecha-
nisms underlying the etiologies remain largely unclear
[22-24]. The inferred relationship between arsenic and
lung cancer is established in CTD via curated interactions
with 18 genes. Notably, IPA analysis of these genes iden-
tified a network involving 72% of these genes (AREG,
BIRC5, EGFR, ERBB2, ESR1, GCLC, HMOX1, KRAS,
MAP3K8, MAPK14, PIK3CA, RASSF1, TGFA). This net-
work suggests that these genes may function coordinately
and form a basis for investigating a mechanistic connec-
tion between arsenic and lung cancer. CTD enables analy-
ses that will lead to the development of novel hypotheses
about the molecular etiologies of environmental diseases.
Discussion
CTD provides curated and integrated toxicological data to
facilitate hypotheses about chemical-gene interaction net-
works and the impact of chemical exposures on human
diseases. Knowledge derived from CTD has potential for
predicting toxicity, identifying biomarkers of exposures,
and unveiling putative therapeutic targets for diseases.
Here we describe how CTD can be used to explore chem-
ical-gene-disease associations using arsenic as a test case.
Arsenic represents a global environmental health threat
and is associated with a wide variety of diseases such as
cancers (skin, bladder, kidney, colon), skin lesions, neu-
ropathies, memory defects, cardiovascular disorders
(atherosclerosis, hypertension), diabetes, anemia, and
respiratory stress [19-21]. Despite its global impact, the
molecular basis of arsenic-induced disease is still not
clear. To provide insight into these mechanisms, we have
curated arsenic-gene interactions and arsenic-disease rela-
tionships reported in the literature using controlled
vocabularies for chemicals, genes, organisms, molecular
actions, and diseases. These vocabularies are key for
allowing flexible querying, consistent retrieval, and com-
plex data analysis. Integration of curated chemical-gene
interactions with other important data sets such as dis-
eases, sequences, GO annotations, KEGG pathways, and
published references creates a unique method for generat-
ing insight into the molecular actions and potential
health effects of diverse chemicals.
At the time of this analysis, CTD contained 2,738 curated
interactions between 1,456 genes and 21 arsenic com-
pounds. Since the chemistry and biotransformation of
arsenic is complex and different compounds can result in
similar arsenic metabolites [18], we analyzed data for all
arsenic compounds collectively. We acknowledge that
there are many complex issues associated with chemical
exposures, such as dose, route, duration, metabolism, and
developmental stage of exposure. Although these issues
are not addressed directly in CTD, all curated data is
hyperlinked to the original source for researchers who
require those details. The predominant molecular effect of
arsenic is alteration of gene transcription. Arsenic com-
pounds also affect activity, phosphorylation status,
Table 4: GO and KEGG annotations for arsenic-interacting 
genes
GO-Molecular Function (top 10 out of 1042 total) Genes1
Protein binding 826
Metal ion binding 261
DNA binding 254
Nucleotide binding 243
ATP binding 203
Zinc ion binding 193
Transferase activity 181
Hydrolase activity 173
Transcription factor activity 157
Receptor activity 152
GO-Biological Process (top 10 out of 2093 total) Genes1
Regulation of transcription, DNA-dependent 229
Signal transduction 227
Transcription 190
Multicellular organismal development 130
Apoptosis 121
Transport 121
Protein amino acid phosphorylation 112
Cell cycle 110
Immune response 104
Cell proliferation 88
GO-Cellular Component (top 10 out of 383 total) Genes1
Nucleus 493
Cytoplasm 464
Membrane 438
Integral to membrane 295
Extracellular space 266
Extracellular region 216
Plasma membrane 176
Intracellular 156
Cytosol 121
Integral to plasma membrane 116
KEGG Pathway (top 10 out of 182 total) Genes1
MAPK signaling pathway 89
Cytokine-cytokine receptor interaction 77
Focal adhesion 72
Cell cycle 56
Apoptosis 48
p53 Signaling pathway 44
Toll-like receptor signaling pathway 42
Regulation of actin cytoskeleton 41
ErbB Signaling pathway 39
Jak-STAT signaling pathway 38
1 Some genes are counted in more than one annotation categoryBMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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metabolism, localization, and secretion of proteins. In
addition, several proteins influenced susceptibility to
arsenic, its metabolism, and its transport.
GO, KEGG pathway, and gene network analyses of
arsenic-responsive genes in CTD provided broad insights
into the diverse biological functions and pathways
affected by arsenic. The most frequently curated gene
Arsenic-responsive interactome Figure 2
Arsenic-responsive interactome. Arsenic-interacting genes were evaluated for enrichment of molecular interactions. Inge-
nuity Pathway Analysis identified a large interaction network of 105 proteins enriched with roles in cell cycle control, apopto-
sis, DNA repair, and associated significantly with cancer (p < 10-34 based on the hypergeometric distribution and calculated 
with the right-tailed Fisher's Exact Test; dotted and solid lines indicate indirect and direct interactions, respectively).BMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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interacting with arsenic was the heme oxidase HMOX1, a
known stress response protein. HMOX1 was originally
discovered as an enzyme involved in the degradation of
heme, but has since been found to play a role in many
other cellular processes, such as protection against nox-
ious stimuli [25]. HMOX1 is regulated by a wide variety of
stress-responsive transcription factors, including mem-
bers of the heat-shock, nuclear factor-kappaB, nuclear fac-
tor-erythroid 2, and activator protein-1 transcription
factor families [25]. Notably, 14 members of these fami-
lies also have curated arsenic interactions in CTD (Figure
1, Table 3, and data not shown), supporting a hypothesis
that arsenic may induce a diverse transcriptional cascade.
Curated chemical-gene interactions in CTD may be used
to develop insight into how complex interactive networks
of genes and proteins are influenced by environmental
chemicals.
Curated data in CTD complement data from recent micro-
array reports of global transcriptional effects of arsenic.
Andrew et al. reported 206 genes with significantly altered
expression in lymphocytes from 21 U.S. citizens exposed
to arsenic-contaminated drinking-water [26]. Among
those genes, 20 currently have curated arsenic interactions
in CTD. The group also mapped their 206 genes to the
same GO and KEGG pathway annotations that we found
in our analysis of 1,456 genes, including immune
response, signal transduction, apoptosis, cell cycle, cell
proliferation, and JAK-STAT pathway. Similarly, Fry et al.
identified three sets of genes that were highly predictive of
arsenic exposure in specific human populations [27].
These arsenic-responsive sets consisted of 151, 34, and 11
genes. Notably, CTD had curated arsenic interactions for
15%, 38%, and 64% of the genes from each set, respec-
tively, substantiating the potential value of CTD for iden-
tifying biomarkers of chemical exposure.
CTD is valuable in refining biomarker candidates and
addressing questions about whether a gene is responsive
to a specific chemical or representative of a more general
stress response. Specifically, the breadth of chemical rep-
resentation and curated data in CTD enables researchers
to compare interacting genes for multiple chemicals or
chemical categories. Interacting genes in CTD were com-
pared between arsenic and other environmental chemi-
cals in CTD, including heavy metals (1,489 genes),
estradiol (1,230 genes), and dioxins (502 genes). Over-
lapping genes were removed, identifying 795 genes that
were unique to arsenic action. CTD may be used alone or
in combination with experimental methods such as
microarray analysis to refine or provide additional confi-
dence in putative biomarkers of environmental exposure.
CTD may be used to develop hypotheses about relation-
ships between environmental chemicals and human dis-
eases. Among the arsenic-interacting genes in CTD, 424
are independently associated with a disease. The associa-
tive structure in CTD allows inferred arsenic-disease rela-
tionships to be constructed. Many of these inferred
diseases were corroborated in the literature (e.g., cancer,
neuropathies, skin lesions, metabolic disorders, and car-
diovascular diseases, amongst others), thereby supporting
the curation and integration paradigms of CTD for devel-
oping testable hypotheses about chemical-disease rela-
tionships.
The molecular basis of most arsenic-induced disease is
still not clear. CTD can offer inroads to discovering such
molecular mechanisms. Inferred chemical-disease associ-
ations create a foundation for developing hypotheses
about relationships between chemicals, genes, diseases,
and the mechanisms of environmentally influenced dis-
eases. For example, CTD users may identify genes that
interact with arsenic and are independently associated
with a neoplasm, such as the 18 arsenic-interacting genes
associated with lung cancer (Table 6). These genes may be
leveraged for experimental or epidemiological studies
with specific emphasis on understanding arsenic-associ-
ated lung cancer such as evaluating polymorphisms in
these genes from lung cancer patients in arsenic-exposed
vs. control regions, testing the value of these genes or their
Table 5: Diseases associated with arsenic-interacting genes
Disease Category Genes1
Neoplasms 177
Nervous system 147
Skin 140
Digestive system 97
Metabolic 86
Immune system 70
Disorders of environmental origin 65
Female urogenital 51
Musculoskeletal 51
Hematologic 48
Cardiovascular 45
Male urogenital 45
Endocrine system 44
Respiratory tract 42
Mental disorders 30
Eye 24
Stomatognathic (mouth, tooth) 22
Virus 21
Lymphatic 15
Connective tissue 14
Bacterial infections 9
Parasitic 8
Nutrition disorders 7
Otorhinolaryngologic (ear, nose, throat) 7
Pregnancy complications 5
Infection 2
1 Some genes occur in more than one disease categoryBMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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products as biomarkers in exposed vs control popula-
tions, or investigating possible interactions between these
proteins in lung cancer cell lines. Similarly, the literature
supports a relatively new correlation between chronic
arsenic exposure and diabetes [28,29]. Among the arsenic-
interacting genes in CTD, 105 are associated with diabetes
directly or are annotated with a GO term or KEGG path-
way involved in insulin or glucose signaling or metabo-
lism, providing a basis for examining the etiology of
arsenic-associated diabetes.
Arsenic is associated with diverse diseases. This diversity
may reflect the broad scope of genes that interact with
arsenic (Tables 3 and 4). It is possible that alteration of
proteins such as transcription factors or receptors that
affect expression of many downstream genes and broad
cellular processes may result in different phenotypic out-
comes. Recent reports have postulated that arsenic may
act as an endocrine disruptor, affecting the signaling path-
ways of steroid hormone receptors, and this dysregulation
may contribute to the diverse nature of arsenic-associated
diseases [30,31]. Interestingly, among arsenic-interacting
genes in CTD, 73 genes (5%) are annotated with a GO
term or KEGG pathway associated with hormone/steroid
metabolism or signaling. In addition, breast cancer (a ster-
oid hormone-associated malignancy) is associated with
the largest number of arsenic-interacting genes in CTD
(Table 6).
In addition to providing data for environmental chemi-
cals, CTD also includes abundant data for therapeutic
chemicals. For example, arsenic trioxide is commonly
used to treat acute leukemia and other cancers [32-35].
Genes that interact with arsenic trioxide in CTD can be
analyzed to look for common biological processes or
pathways associated with arsenic trioxide therapy. CTD
could be used to better define the molecular pathways and
genes targeted by arsenic trioxide for the purpose of devel-
oping alternative therapeutic agents to circumvent chemi-
cal resistance or toxicity.
Conclusion
CTD provides curated chemical-gene interactions and
integrates this data with gene, disease, reference, GO
annotation, KEGG pathway, organism, and sequence
information to enhance understanding about the effects
of chemicals on molecular networks and human diseases.
Using arsenic as a test case, we report 2,738 molecular
interactions between 21 different arsenic compounds and
1,456 genes/proteins. Analyses of these genes provide
insight into the biological functions and molecular net-
works that are affected by exposure to arsenic. Integrating
Arsenic-gene-disease predictions Figure 3
Arsenic-gene-disease predictions. CTD describes a molecular interaction between arsenic (As) and 1,456 genes; 424 of 
those genes are also directly associated with a disease. The integration of these two data sets predicts diseases that parallel 
those already known to be associated with arsenic exposure, underscoring the potential value and validity of these inferred 
relationships.BMC Medical Genomics 2008, 1:48 http://www.biomedcentral.com/1755-8794/1/48
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this arsenic-gene data set with a gene-disease data set
yields a list of 516 putative diseases that interestingly par-
allel known arsenic-associated diseases categories. This
work demonstrates and validates the utility of CTD for
understanding the molecular networks and biological
functions affected by chemicals. In this respect, CTD may
be used as a tool to provide connections between chemi-
cals, genes, and diseases that may not otherwise be appar-
ent, and may provide the basis for testable hypotheses
about the mechanisms underlying the etiology of envi-
ronmental diseases. The analysis reported here for arsenic
should be applicable to any environmental chemical or
therapeutic drug.
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